Patents by Inventor Neelu Kaila

Neelu Kaila has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof
    Patent number: 10385036
    Abstract: The present invention provides sulfonamide-substituted indoles and Methods of Use Thereof-substituted pyrrolopyridines, pharmaceutical compositions thereof methods of modulating RORy activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such indoles and pharmaceutical compositions thereof.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: August 20, 2019
    Assignee: Pfizer Inc.
    Inventors: Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Goran Mattias Wennerstal, Li Xing, Edouard Zamaratski, Liying Zhang, Rayomand J. Unwalla
  • Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
    Patent number: 10336748
    Abstract: The present invention provides methoxy-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: July 2, 2019
    Assignee: Pfizer Inc.
    Inventors: Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Goran Mattias Wennerstal, Li Xing, Edouard Zamaratski, Liying Zhang, Rayomand J. Unwalla
  • Methyl- and Trifluromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof
    Publication number: 20190150401
    Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
    Type: Application
    Filed: February 6, 2019
    Publication date: May 23, 2019
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Goran Mattias Wennerstal, Li Xing, Edouard Zamaratski, Liying Zhang, Rayomand Jal Unwalla
  • RORC2 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20190144429
    Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
    Type: Application
    Filed: January 30, 2019
    Publication date: May 16, 2019
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Gõran Mattias Wennerstål, James Robert Blinn, Neelu Kaila, James Richard Kiefer, JR., Scot Richard Mente, Ravi G. Kurumbail, Marvin Jay Meyers, Atli Thorarensen, Li Xing, Christoph Wolfgang Zapf, Edouard Zamaratski, Andrew Christopher Flick, Peter Jones
  • Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof
    Patent number: 10227346
    Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: March 12, 2019
    Assignee: Pfizer Inc.
    Inventors: Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Goran Mattias Wennerstal, Li Xing, Edouard Zamaratski, Liying Zhang, Rayomand Jal Unwalla
  • RORC2 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20180282304
    Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
    Type: Application
    Filed: June 14, 2018
    Publication date: October 4, 2018
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Göran Mattias Wennerstål, James Robert Blinn, Neelu Kaila, James Richard Kiefer, JR., Scot Richard Mente, Ravi G. Kurumbail, Marvin Jay Meyers, Atli Thorarensen, Li Xing, Christoph Wolfgang Zapf, Edouard Zamaratski, Andrew Christopher Flick, Peter Jones
  • Sulfonamide-Substituted Indole Modulators of RORC2 and Methods of Use Thereof
    Publication number: 20180273504
    Abstract: The present invention provides sulfonamide-substituted indoles and Methods of Use Thereof-substituted pyrro-lopyridines, pharmaceutical compositions thereof methods of modulating RORy activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such indoles and pharmaceutical compositions thereof.
    Type: Application
    Filed: January 29, 2016
    Publication date: September 27, 2018
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Goran Mattias Wennerstal, Li Xing, Edouard Zamaratski, Liying Zhang, Rayomand J. Unwalla
  • Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof
    Publication number: 20180170928
    Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
    Type: Application
    Filed: February 6, 2018
    Publication date: June 21, 2018
    Applicant: Pfizer Inc.
    Inventors: MARK EDWARD SCHNUTE, ANDREW CHRISTOPHER FLICK, PETER JONES, NEELU KAILA, SCOT RICHARD MENTE, JOHN DAVID TRZUPEK, MICHAEL L. VAZQUEZ, GORAN MATTIAS WENNERSTAL, LI XING, EDOUARD ZAMARATSKI, LIYING ZHANG
  • RORC2 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20180086736
    Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
    Type: Application
    Filed: December 7, 2017
    Publication date: March 29, 2018
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Göran Mattias Wennerstål, James Robert Blinn, Neelu Kaila, James Richard Kiefer, JR., Scot Richard Mente, Ravi G. Kurumbail, Marvin Jay Meyers, Atli Thorarensen, Li Xing, Christoph Wolfgang Zapf, Edouard Zamaratski, Andrew Christopher Flick, Peter Jones
  • Methyoxy-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof
    Publication number: 20180002330
    Abstract: The present invention provides methoxy-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
    Type: Application
    Filed: January 29, 2016
    Publication date: January 4, 2018
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Goran Mattias Wennerstal, Li Xing, Edouard Zamaratski, Liying Zhang, Rayomand J. Unwalla
  • RORC2 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20170233371
    Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
    Type: Application
    Filed: April 26, 2017
    Publication date: August 17, 2017
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Gõran Mattias Wennerstål, James Robert Blinn, Neelu Kaila, James Richard Kiefer, Jr., Scot Richard Mente, Ravi G. Kurumbail, Marvin Jay Meyers, Atli Thorarensen, Li Xing, Christoph Wolfgang Zapf, Edouard Zamaratski, Andrew Christopher Flick, Peter Jones
  • Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof
    Publication number: 20170233390
    Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
    Type: Application
    Filed: April 28, 2017
    Publication date: August 17, 2017
    Applicant: Pfizer Inc.
    Inventors: MARK EDWARD SCHNUTE, ANDREW CHRISTOPHER FLICK, PETER JONES, NEELU KAILA, SCOT RICHARD MENTE, JOHN DAVID TRZUPEK, MICHAEL L. VAZQUEZ, GÖRAN MATTIAS WENNERSTÅL, LI XING, EDOUARD ZAMARATSKI, LIYING ZHANG
  • Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
    Patent number: 9670201
    Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: June 6, 2017
    Assignee: Pfizer Inc.
    Inventors: Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Göran Mattias Wennerstål, Li Xing, Edouard Zamaratski, Liying Zhang
  • Pyrrolo[2,3-D]pyrimidine derivatives
    Patent number: 9549929
    Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: January 24, 2017
    Assignee: Pfizer Inc.
    Inventors: Matthew Frank Brown, Ashley Edward Fenwick, Mark Edward Flanagan, Andrea Gonzales, Timothy Allan Johnson, Neelu Kaila, Mark J. Mitton-Fry, Joseph Walter Strohbach, Ruth E. TenBrink, John David Trzupek, Rayomand Jal Unwalla, Michael L. Vazquez, Mihir D. Parikh
  • Pyrrolo[2,3-D]pyrimidine derivatives
    Patent number: 9545405
    Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: January 17, 2017
    Assignee: Pfizer Inc.
    Inventors: Matthew Frank Brown, Ashley Edward Fenwick, Mark Edward Flanagan, Andrea Gonzales, Timothy Allan Johnson, Neelu Kaila, Mark J. Mitton-Fry, Joseph Walter Strohbach, Ruth E. TenBrink, John David Trzupek, Rayomand Jal Unwalla, Michael L. Vazquez, Mihir D. Parikh
  • Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof
    Publication number: 20160090381
    Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
    Type: Application
    Filed: September 24, 2015
    Publication date: March 31, 2016
    Inventors: MARK EDWARD SCHNUTE, ANDREW CHRISTOPHER FLICK, PETER JONES, NEELU KAILA, SCOT RICHARD MENTE, JOHN DAVID TRZUPEK, MICHAEL L. VAZQUEZ, GÖRAN MATTIAS WENNERSTÅL, LI XING, EDOUARD ZAMARATSKI, LIYING ZHANG
  • RORC2 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20160046597
    Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
    Type: Application
    Filed: July 31, 2014
    Publication date: February 18, 2016
    Inventors: Mark Edward Schnute, Göran Mattias Wennerstål, James Robert Blinn, Neelu Kaila, James Richard Kiefer, JR., Scot Richard Mente, Ravi G. Kurumbail, Marvin Jay Meyers, Atli Thorarensen, Li Xing, Christoph Wolfgang Zapf, Edouard Zamaratski, Andrew Christopher Flick, Peter Jones
  • PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES
    Publication number: 20160045508
    Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing them, and therapeutic uses thereof.
    Type: Application
    Filed: August 10, 2015
    Publication date: February 18, 2016
    Applicant: Pfizer Inc.
    Inventors: Michael L. VAZQUEZ, Neelu KAILA, Jamison B. TUTTLE, Patrick Robert VERHOEST, Matthew R. REESE, Karen J. COFFMAN, Tarek SAMAD, James M. DUERR, Simone SCIABOLA, Mihir D. PARIKH
  • PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES
    Publication number: 20150246048
    Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
    Type: Application
    Filed: May 18, 2015
    Publication date: September 3, 2015
    Inventors: Matthew Frank Brown, Ashley Edward Fenwick, Mark Edward Flanagan, Andrea Gonzales, Timothy Allan Johnson, Neelu Kaila, Mark J. Mitton-Fry, Joseph Walter Strohbach, Ruth E. TenBrink, John David Trzupek, Rayomand Jal Unwalla, Michael L. Vazquez, Mihir D. Parikh
  • PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES
    Publication number: 20150225408
    Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
    Type: Application
    Filed: April 21, 2015
    Publication date: August 13, 2015
    Inventors: Matthew Frank Brown, Ashley Edward Fenwick, Mark Edward Flanagan, Andrea Gonzales, Timothy Allan Johnson, Neelu Kaila, Mark J. Mitton-Fry, Joseph Walter Strohbach, Ruth E. TenBrink, John David Trzupek, Rayomand Jal Unwalla, Michael L. Vazquez, Mihir D. Parikh